Molbio Diagnostics Targets ₹940 Crore Through IPO for Expansion

Molbio Diagnostics, a key player in the molecular diagnostics sector, is set to launch an initial public offering (IPO) aiming to raise ₹940 crore. The company plans to use ₹200 crore from a fresh issue of shares to bolster its capital expenditures, while an additional ₹740 crore will be generated through an offer for sale, effectively reducing the promoter group's stake from 46.6% to 43%.

Global Reach and Product Focus

Founded in 2000, Molbio Diagnostics has established a significant presence in over 90 countries, operating six manufacturing facilities across India. The company's portfolio includes diagnostic solutions for both infectious and non-communicable diseases. A notable contribution to its revenue comes from the 'Truenat' platform, a portable diagnostic system that provides accurate test results in under an hour, particularly beneficial in resource-limited settings.

Molbio's revenue is heavily dependent on its tuberculosis diagnostic test kits, which account for 70% of test kit sales. Government and international aid agencies are major clients, contributing to over 80% of the company's revenue.

Financial Performance and Market Position

Between FY24 and FY26, Molbio reported a 31.5% increase in revenue from operations, reaching ₹1,445.7 crore. During the same period, net profit surged by 40.2% to ₹164.1 crore, while EBITDA grew by 33.2% to ₹328.2 crore, with margins improving to 22.6% in FY26 from 22% in FY24.

The company's valuation post-IPO suggests a price-earnings multiple of up to 57. This positions Molbio competitively against other healthcare diagnostics and medical device companies, such as Poly Medicure and Dr. Lal PathLabs, which have P/E multiples ranging from 54 to 81.

Investor Considerations

Despite its concentrated customer base, with over half of its revenue coming from top clients, Molbio's robust financial performance and strategic market positioning make it a potentially attractive option for investors with a high-risk appetite. The company's commitment to expanding its operations and reducing promoter stake through the IPO could signal long-term growth potential.